Our featured projects
Partnering in the search for a vaccine against malaria
RTS,S malaria vaccine candidate
GlaxoSmithKline Biologicals’ RTS,S is the malaria vaccine candidate farthest along in the development process. In clinical trials conducted over the past decade, this vaccine candidate demonstrated that it can provide significant protection for young children and infants in malaria-endemic areas against infection, clinical disease, and severe disease caused by Plasmodium falciparum malaria. Learn more on the MVI website about the RTS,S vaccine candidate (432 KB PDF).
Pfs25 antigen in transmission-blocking vaccines
MVI is collaborating with the National Institute of Allergy and Infectious Diseases and Johns Hopkins Bloomberg School of Public Health Center for Immunization Research to evaluate a potential transmission-blocking vaccine candidate—Pfs25—in a phase 1 clinical trial in adults. Transmission-blocking vaccines aims to block transmission of malaria from mosquitoes to humans by preventing the malaria parasite from developing in the mosquito. They have the potential to significantly limit the spread of malaria infection. This is the first clinical trial using a transmission-blocking approach to be supported by MVI.